VSTM Q4 2021 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$545,000+7.7% YoY

Gross Profit

$545,000100.0% margin

Operating Income

-$17M-3029.5% margin

Net Income

-$16M-3024.0% margin

EPS (Diluted)

$-1.08

QoQ Revenue Growth

+27150.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$109M

Total Liabilities

$21M

Stockholders' Equity

$88M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$545,000	$506,000	+7.7%
Gross Profit	$545,000	$494,000	+10.3%
Operating Income	-$17M	-$17M	+1.5%
Net Income	-$16M	-$20M	+17.0%

Revenue Segments

Copiktra license and related assets

$545,000100%